EVEKEO ODT

Peak

amphetamine sulfate

R-Pharm US
NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jan 2019
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.

Indications (3)

Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 yearsolderinsomnia

Loss of Exclusivity

LOE Date
Mar 10, 2037
134 months away
Patent Expiry
Mar 10, 2037

Patent Records (3)

Patent #ExpiryTypeUse Code
10441554
Mar 10, 2037
Product
—
11160772
Mar 10, 2037
Product
—
11896562
Mar 10, 2037
U-3299
Company
R-Pharm US
R-Pharm US
NJ - Princeton
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers